Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore
Authors:
- 1 May 2012
- journal article
- Published by Elsevier in Value in Health Regional Issues
- Vol. 1 (1) , 66-74
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp & Dohme
This publication has 16 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnnals of Oncology, 2010
- AprepitantDrugs, 2009
- Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in BelgiumSupportive Care in Cancer, 2007
- Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic ChemotherapyValue in Health, 2007
- Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in GermanyEuropean Journal of Cancer, 2007
- Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic ChemotherapyJournal of Clinical Oncology, 2005
- AprepitantDrugs, 2004
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonistsBritish Journal of Cancer, 1997